Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
Saved in:
Main Authors: | Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont, Steven Le Gouill, Riccardo Masetti, Davide Gori, Alessandro Broccoli, Pier Luigi Zinzani, Lisa Argnani |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2024-11-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-024-01183-8 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dreams Cars /
by: Philip, Sam
Published: (2014) -
ErbB- and MUC1-targeted CAR-T cell immunotherapy of oral squamous cell carcinoma
by: Saffron E. Summers, et al.
Published: (2023-03-01) -
Dual-targeting CAR T cells for B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma
by: Gustavo de Oliveira Canedo, et al.
Published: (2025-02-01) -
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
by: Elise A. Chong, et al.
Published: (2025-02-01) -
CAR T-cell detection scoping review: an essential biomarker in critical need of standardization
by: Naomi Taylor, et al.
Published: (2023-05-01)